Guardant Health and Quest Diagnostics Collaborate to Expand Access to Colorectal Cancer Screening

What's Happening?

Guardant Health, a precision oncology company, and Quest Diagnostics, a leader in diagnostic information services, have announced a strategic collaboration to broaden access to Guardant's Shield™ blood-based screening test for colorectal cancer in the United States. Shield is the first blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. This collaboration will allow Quest's provider clients to order the Shield test directly through their existing Quest accounts and electronic health records. Quest will also facilitate patient access to the test through its extensive network of service centers and phlebotomists. The Shield test is expected to be available for order through Quest in the first quarter of 2026.

Why It's Important?

This collaboration is significant as it aims to increase the accessibility and convenience of colorectal cancer screening, potentially improving early detection rates. Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with a high survival rate if detected early. However, many eligible adults avoid screening due to the unpleasant nature of traditional methods like colonoscopies and stool tests. The Shield test, which requires only a simple blood draw, could reduce these barriers, encouraging more people to undergo screening. This could lead to earlier detection and treatment, ultimately improving patient outcomes and reducing mortality rates associated with colorectal cancer.

What's Next?

As the Shield test becomes available through Quest Diagnostics, there will likely be an increase in awareness and adoption among healthcare providers and patients. Quest's national commercial sales team will play a crucial role in educating primary care physicians and obstetricians and gynecologists about the test. The collaboration is expected to enhance the reach of advanced diagnostics, potentially setting a precedent for similar partnerships in the future. The healthcare industry will be watching closely to see how this collaboration impacts screening rates and patient outcomes.